Granted Patent B2

US 12,280,226 · App. 18/436,480 · Granted Apr 22, 2025

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN); David Hendrickson (Coon Rapids, MN)

Assignee: Urotronic, Inc.

A61M25/1002A61L29/06A61L29/08A61L29/085A61L29/16A61B1/00082A61B1/307A61L2300/416A61L2300/426A61M2025/0081A61M25/10185A61M2025/105A61M2025/1059A61M2025/1075A61M2202/0488A61M2205/0205A61M2210/0681A61M2210/105A61M2210/1085A61M2210/1096A61M2210/166

Abstract

Claims (24)

1. A method of treating a target site in body lumen, the method comprising:

inserting a balloon catheter into the target site in the body lumen, the balloon catheter comprising an elongated balloon comprising at least one neck section, the balloon comprising a first main section and a second main section on opposite sides of the neck section;

inflating the balloon catheter, wherein the first main section and second main section have a main diameter when the balloon is inflated, the at least one neck section comprises an inflated diameter that is smaller than the inflated main diameter of the first and second sections, and the inflated diameter of the neck section is the smallest diameter of the balloon catheter between the first main section and the second main section when the balloon is inflated;

deflating the balloon catheter; and

withdrawing the balloon catheter from the body lumen.

2. The method of claim 1 , wherein the target site in the body lumen is a target site in a vascular lumen, a nonvascular lumen, a coronary artery, a peripheral artery, a urethra, a ureter, a prostatic urethra, an esophagus, a biliary tract, a stomach, a small intestine, a duodenum, a jejunum, an ileum, a colon, a rectum, a large intestine, a sinus, or an airway.

3. The method of claim 1 , wherein the target site in the body lumen comprises a body lumen stricture.

4. The method of claim 1 , wherein the at least one neck section comprises an area of reduced compliance during inflation relative to the first main section and the second main section.

5. The method of claim 1 , wherein the at least one neck section comprises a reinforcing material around a circumference of the neck section.

6. The method of claim 1 , wherein the body lumen comprises a scope, wherein the method further comprises positioning the balloon catheter and the scope side-by-side or loading the balloon catheter into the scope.

7. The method of claim 6 , wherein the method comprises loading the balloon catheter into the scope.

8. The method of claim 6 , wherein the balloon catheter is visualizable with the scope.

9. The method of claim 1 , wherein the balloon catheter comprises a coating layer overlying an exterior surface of the balloon.

10. The method of claim 9 , wherein prior to the inflating of the balloon catheter, the balloon is soaked or flushed in a solution comprising water, saline, or water comprising at least one water-soluble additive.

11. The method of claim 10 , further comprising flushing the target site in the body lumen with the solution prior to or during the inflating of the balloon catheter.

12. The method of claim 10 , further comprising soaking the coating layer of the balloon catheter in the solution outside the body prior to the inserting of the balloon catheter into the body lumen stricture.

13. The method of claim 9 , wherein the coating layer is on the first main section and the neck.

14. The method of claim 9 , wherein the coating layer comprises one or more water-soluble additives.

15. The method of claim 14 , wherein the one or more water-soluble additives in the coating layer comprise pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate/ethoxylate, N-acetylglucosamine, N-octyl-D-gluconamide, N-nonanoyl-N-methylglycamine, N-octanoyl-N-methyl glutamine, C6-ceramide, dihydro-C6-ceramide, cerabroside, sphingomyelin, galaclocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octonoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, polyethylene glycol (PEG) caprylic/capric diglycerides, PEG-8 caprylic/capric glycerides, PEG caprylate, PEG-8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, monolaurin, monocaprin, monocaprylin, monomyristin, monopalmitolein, monoolein, creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthosine, xanthosine monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N′-bis(hydroxymethyl) urea, glycerol ethoxylate, glycerol propoxylate, trimethylolpropane ethoxylate, pentaerythritol, dipentaerythritol, crown ether, 18-crown-6, 15-crown-5, 12-crown-4, or combinations thereof.

16. The method of claim 14 , wherein the one or more water-soluble additives in the coating layer comprise pentaerythritol ethoxylate (15/4) and/or pentaerythritol ethoxylate (3/4).

17. The method of claim 14 , wherein the one or more water-soluble additives in the coating layer comprise pentaerythritol ethoxylate (15/4) and pentaerythritol ethoxylate (3/4).

18. The method of claim 17 , wherein the coating layer comprises paclitaxel, wherein a mass ratio of the paclitaxel to the pentaerythritol ethoxylate (15/4) and the pentaerythritol ethoxylate (3/4) is 1:5.5 to 10:1 and a mass ratio of the pentaerythritol ethoxylate (15/4) to the pentaerythritol ethoxylate (3/4) is 1:40 to 7.5:1.

19. The method of claim 9 , wherein the coating layer comprises a therapeutic agent that comprises paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof.

20. The method of claim 19 , wherein the therapeutic agent comprises paclitaxel.

Assignments (1)

Continuity (10)

References Cited (400)